CL
PLX icon

CSS LLC’s Protalix BioTherapeutics PLX Stock Holding History

CSS LLC’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,410
Closed -$94K – 716
2013
Q4 		$94K Buy
+2,410
New +$101K ﹤0.01% 628

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

CSS LLC's PLX Position: Q1 2014 in Review

CSS LLC sold out of Protalix BioTherapeutics (PLX) in Q1 2014, closing a stake of 2,410 shares — an estimated $94K sold.

CSS LLC first reported a position in PLX in Q4 2013 and held it in 1 quarter. The position peaked at $94K in Q4 2013. 44 funds tracked by Wall St. Rank hold PLX as of Q1 2014.

  • CSS LLC reported no remaining Protalix BioTherapeutics position as of Q1 2014 after selling out during the quarter.
  • CSS LLC sold 2,410 Protalix BioTherapeutics shares in Q1 2014, an estimated $94K.
  • CSS LLC first reported a position in Protalix BioTherapeutics in Q4 2013 and held it in 1 quarter.
  • CSS LLC's Protalix BioTherapeutics position peaked at $94K in Q4 2013.
  • 44 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2014.

Based on CSS LLC's 13F filing for Q1 2014, filed 15 May 2014.